Safety assessment of potential probiotic Lactobacillus acidophilus AM13-1 with high cholesterol-lowering capability isolated from human gut.

Xiaoqian Lin, Wenxi Li, Lan Ge, Shaowei Zhao, Yuanqiang Zou, Yiyi Zhong, Liang Xiao, Xudong Liu, Haifeng Zhang, Mengmeng Wang, Xin Jin, Tongyuan Hu, Hewei Liang

Journal: Letters in applied microbiology 2024;77(1):

PMID: 38126115

Abstract

An important risk factor for cardiovascular disease is dyslipidemia, especially abnormal cholesterol levels. The relation between probiotics and cholesterol-lowering capability has been extensively studied. Lactobacillus acidophilus plays a significant role in affecting host health, and produces multitudinous metabolites, which have prohibitory functions against pathogenic microorganisms. In this study, we identified a cholesterol-lowering strain AM13-1, isolated from a fecal sample obtained from a healthy adult male, and performed comprehensive function analysis by whole-genome analysis and in vitro experiments. Genome analyses of L. acidophilus AM13-1 revealed that carbohydrate and amino acid transport, metabolism, translation, ribosomal structure, and biogenesis are abundant categories of functional genes. No virulence factors or toxin genes with experimentally verified were found in the genome of strain AM13-1. Besides, plenty of probiotic-related genes were predicted from the L. acidophilus AM13-1 genome, such as cbh, atpA-D, and dltD, with functions related to cholesterol-lowering and acid resistance. And strain AM13-1 showed high-efficiency of bile salt hydrolase activity and the capacity for removing cholesterol with efficiency rates of 70%. These function properties indicate that strain AM13-1 can be considered as a probiotic candidate for use in food and health care products.

© The Author(s) 2023. Published by Oxford University Press on behalf of Applied Microbiology International.

Address: BGI Research, Shenzhen 518083, China.; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.; BGI Research, Shenzhen 518083, China.; BGI Research, Wuhan 430074, China.; BGI Research, Shenzhen 518083, China.; School of Bioscience and Biotechnology, South China University of Technology, Guangzhou 510006, China.; BGI Research, Shenzhen 518083, China.; BGI Research, Shenzhen 518083, China.; BGI Precision Nutrition, Shenzhen 518083, China.; BGI Research, Shenzhen 518083, China.; BGI Research, Wuhan 430074, China.; Lars Bolund Institute of Regenerative Medicine Qingdao-Europe Advanced Institute for LifeSciences, BGI Research, Qingdao 266555, China.; Shenzhen Engineering Laboratory of Detection and Intervention of Human Intestinal Microbiome, BGI Research, Shenzhen 518083, China.; BGI College and Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.